-
Communities
-
Explore Vanderbilt communities
By latest
Featured community
Creative Data Solutions (CDS) is a Vanderbilt Shared Resource and has extensive experience in providing effective and robust solutions to challenges pertaining to research data using modern informatics and bioinformatics approaches.
-
- Resources
-
People
-
Publications
-
Explore publications
-
Keyword Connections
Connections to Sirolimus are shown below. Double-click or tap a node for more information.
Please note that publication matches are limited to 40 in this view. If you expected more, please view all publication matches for Sirolimus.
Members
- No matching connections
Resources
- No matching connections
Communities
- No matching connections
Publications
- Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial
(2007) N Engl J Med 356: 2271-81 - Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG
(2013) Lancet Oncol 14: 371-82 - The targeted podocyte.
Fogo AB
(2011) J Clin Invest 121: 2142-5 - Phosphatidylinositol 3-kinase signaling determines kidney size.
Chen JK, Nagai K, Chen J, Plieth D, Hino M, Xu J, Sha F, Ikizler TA, Quarles CC, Threadgill DW, Neilson EG, Harris RC
(2015) J Clin Invest 125: 2429-44 - Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL
(2010) J Clin Invest 120: 2406-13 - Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac myocytes and effects on Ca sparks.
Guo T, Cornea RL, Huke S, Camors E, Yang Y, Picht E, Fruen BR, Bers DM
(2010) Circ Res 106: 1743-52 - Synthetic spatially graded Rac activation drives cell polarization and movement.
Lin B, Holmes WR, Wang CJ, Ueno T, Harwell A, Edelstein-Keshet L, Inoue T, Levchenko A
(2012) Proc Natl Acad Sci U S A 109: E3668-77 - ER trapping reveals Golgi enzymes continually revisit the ER through a recycling pathway that controls Golgi organization.
Sengupta P, Satpute-Krishnan P, Seo AY, Burnette DT, Patterson GH, Lippincott-Schwartz J
(2015) Proc Natl Acad Sci U S A 112: E6752-61 - Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy.
Chen JK, Chen J, Neilson EG, Harris RC
(2005) J Am Soc Nephrol 16: 1384-91 - Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.
Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM
(2011) Cancer Res 71: 5965-75 - Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.
Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W
(2011) Cancer Res 71: 4920-31 - New therapies for tuber-less sclerosis: white matter matters?
Ess KC, Roach ES
(2012) Neurology 78: 520-1 - Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL, Othus M, Sosman JA, Kirkwood JM, Sondak VK
(2012) Clin Cancer Res 18: 1129-37 - Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA
(2007) Clin Cancer Res 13: 5150-5 - Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway.
Vilar E, Mukherjee B, Kuick R, Raskin L, Misek DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennert G, Gruber SB
(2009) Clin Cancer Res 15: 2829-39 - Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.
Wan X, Harkavy B, Shen N, Grohar P, Helman LJ
(2007) Oncogene 26: 1932-40 - Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA
(2008) Oncogene 27: 4086-95 - mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.
He K, Zheng X, Li M, Zhang L, Yu J
(2016) Oncogene 35: 148-57 - Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.
Huye LE, Nakazawa Y, Patel MP, Yvon E, Sun J, Savoldo B, Wilson MH, Dotti G, Rooney CM
(2011) Mol Ther 19: 2239-48 - Unleashing rapamycin in fibrosis.
Hillel AT, Gelbard A
(2015) Oncotarget 6: 15722-3 - Improvement in insulin sensitivity after human islet transplantation for type 1 diabetes.
Rickels MR, Kong SM, Fuller C, Dalton-Bakes C, Ferguson JF, Reilly MP, Teff KL, Naji A
(2013) J Clin Endocrinol Metab 98: E1780-5 - An unusual cause of respiratory failure in a 25-year-old heart and lung transplant recipient.
Narotzky S, Kennedy CC, Maldonado F
(2015) Chest 147: e185-e188 - Sirolimus-associated diffuse alveolar hemorrhage.
Vlahakis NE, Rickman OB, Morgenthaler T
(2004) Mayo Clin Proc 79: 541-5 - Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system.
Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, Pumper CP, Kimple ME, Lamming DW
(2016) Aging Cell 15: 28-38 - Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.
Carson RP, Van Nielen DL, Winzenburger PA, Ess KC
(2012) Neurobiol Dis 45: 369-80 - ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.
Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, Schlessinger S, Wang B, Chemburkar SR, Bauch J, Tse C, Frost DJ, Fesik SW, Rosenberg SH, Elmore SW, Shoemaker AR
(2008) Mol Cancer Ther 7: 3265-74 - Tuberous sclerosis complex: a brave new world?
Ess KC
(2010) Curr Opin Neurol 23: 189-93 - Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.
Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL
(2002) Mol Cell Biol 22: 8184-98 - A Rictor-Myo1c complex participates in dynamic cortical actin events in 3T3-L1 adipocytes.
Hagan GN, Lin Y, Magnuson MA, Avruch J, Czech MP
(2008) Mol Cell Biol 28: 4215-26 - Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM
(2011) Eur J Heart Fail 13: 1-10 - Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA
(2007) Cancer 110: 599-605 - Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation.
Vo K, Amarasinghe B, Washington K, Gonzalez A, Berlin J, Dang TP
(2011) Mol Cancer 10: 138 - Zebrafish model of tuberous sclerosis complex reveals cell-autonomous and non-cell-autonomous functions of mutant tuberin.
Kim SH, Speirs CK, Solnica-Krezel L, Ess KC
(2011) Dis Model Mech 4: 255-67 - Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
Kim SH, Kowalski ML, Carson RP, Bridges LR, Ess KC
(2013) Dis Model Mech 6: 925-33 - Induction of the C/EBP homologous protein (CHOP) by amino acid deprivation requires insulin-like growth factor I, phosphatidylinositol 3-kinase, and mammalian target of rapamycin signaling.
Entingh AJ, Law BK, Moses HL
(2001) Endocrinology 142: 221-8 - Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway.
Law BK, Nørgaard P, Gnudi L, Kahn BB, Poulson HS, Moses HL
(1999) J Biol Chem 274: 4743-8 - Phosphorylation regulates the interaction between Gln3p and the nuclear import factor Srp1p.
Carvalho J, Bertram PG, Wente SR, Zheng XF
(2001) J Biol Chem 276: 25359-65 - Interleukin 4-inducible phosphorylation of HMG-I(Y) is inhibited by rapamycin.
Wang DZ, Ray P, Boothby M
(1995) J Biol Chem 270: 22924-32 - Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli.
Law BK, Norgaard P, Moses HL
(2000) J Biol Chem 275: 10796-801 - Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
Willey CD, Xiao D, Tu T, Kim KW, Moretti L, Niermann KJ, Tawtawy MN, Quarles CC, Lu B
(2010) Int J Radiat Oncol Biol Phys 77: 1518-26
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.
